Clinical Trial Update: A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of copanlisib and rucaparib in metastatic castration-resistant prostate cancer; the study is active but…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Copanlisib (copanlisib)
• Rucaparib (rucaparib)

Snippet

Sponsor: Brown University | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING